CR20160200A - Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores - Google Patents
Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladoresInfo
- Publication number
- CR20160200A CR20160200A CR20160200A CR20160200A CR20160200A CR 20160200 A CR20160200 A CR 20160200A CR 20160200 A CR20160200 A CR 20160200A CR 20160200 A CR20160200 A CR 20160200A CR 20160200 A CR20160200 A CR 20160200A
- Authority
- CR
- Costa Rica
- Prior art keywords
- combinations
- inhibitors
- immunomodulating drugs
- subject
- deacetilase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a combinaciones que comprenden un inhibidor de HDAC y un fármaco inmunomodulador para el tratamiento de mieloma múltiple en un sujeto en necesidad del mismo. Las combinaciones, opcionalmente, pueden comprender además un agente antiinflamatorio, tal como dexametasona. También en la presente se proporcionan métodos para tratar el mieloma múltiple en un sujeto en necesidad del mismo que comprenden administrar al sujeto una cantidad efectiva de una de las combinaciones anteriores.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361889640P | 2013-10-11 | 2013-10-11 | |
US201361911089P | 2013-12-03 | 2013-12-03 | |
PCT/US2014/059387 WO2015054175A1 (en) | 2013-10-11 | 2014-10-07 | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160200A true CR20160200A (es) | 2016-08-29 |
Family
ID=52810182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160200A CR20160200A (es) | 2013-10-11 | 2014-10-07 | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
Country Status (17)
Country | Link |
---|---|
US (2) | US20150105358A1 (es) |
EP (1) | EP3054939A4 (es) |
JP (4) | JP2016532667A (es) |
KR (1) | KR20160060143A (es) |
CN (1) | CN105722507A (es) |
AU (1) | AU2014332147A1 (es) |
CA (1) | CA2926808A1 (es) |
CL (1) | CL2016000838A1 (es) |
CR (1) | CR20160200A (es) |
EA (1) | EA201690753A1 (es) |
IL (1) | IL244923A0 (es) |
MX (1) | MX2016004604A (es) |
NI (1) | NI201600051A (es) |
PE (1) | PE20161342A1 (es) |
PH (1) | PH12016500649A1 (es) |
SG (1) | SG11201602791RA (es) |
WO (1) | WO2015054175A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3091004B1 (en) | 2010-01-22 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
SG190211A1 (en) | 2010-11-16 | 2013-06-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
EP3055299B1 (en) * | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
EP3054939A4 (en) * | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
WO2015061684A1 (en) | 2013-10-24 | 2015-04-30 | Mayo Foundation For Medical Education And Research | Treatment of polycystic diseases with an hdac6 inhibitor |
CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
EP3166603B1 (en) | 2014-07-07 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
EP3226903A1 (en) | 2014-12-05 | 2017-10-11 | University of Modena and Reggio Emila | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
EP3292113B1 (en) | 2014-12-12 | 2020-07-08 | Regenacy Pharmaceuticals, LLC | Piperidine derivatives as hdac1/2 inhibitors |
JP6873053B2 (ja) | 2015-06-08 | 2021-05-19 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | タンパク質脱アセチル化阻害剤の製造方法 |
EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
JP7233220B2 (ja) * | 2016-06-09 | 2023-03-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Hdac阻害剤とbet阻害剤の使用方法及びその薬学的組み合わせ |
JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ6阻害剤及びcd20阻害抗体の薬学的組み合わせならびにその使用 |
KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
EP3544600A4 (en) * | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF |
EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
CN117561059A (zh) | 2021-04-23 | 2024-02-13 | 特纳亚治疗股份有限公司 | 用于治疗扩张型心肌病的hdac6抑制剂 |
CA3216768A1 (en) | 2021-05-04 | 2022-11-10 | Jin Yang | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
AU2006313517B2 (en) | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
EP3091004B1 (en) * | 2010-01-22 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
SG190211A1 (en) * | 2010-11-16 | 2013-06-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
US9512083B2 (en) * | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
EP3054939A4 (en) | 2013-10-11 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
-
2014
- 2014-10-07 EP EP14851888.9A patent/EP3054939A4/en active Pending
- 2014-10-07 US US14/508,072 patent/US20150105358A1/en not_active Abandoned
- 2014-10-07 KR KR1020167011860A patent/KR20160060143A/ko not_active Application Discontinuation
- 2014-10-07 CA CA2926808A patent/CA2926808A1/en not_active Abandoned
- 2014-10-07 SG SG11201602791RA patent/SG11201602791RA/en unknown
- 2014-10-07 MX MX2016004604A patent/MX2016004604A/es unknown
- 2014-10-07 PE PE2016000490A patent/PE20161342A1/es not_active Application Discontinuation
- 2014-10-07 JP JP2016521758A patent/JP2016532667A/ja active Pending
- 2014-10-07 WO PCT/US2014/059387 patent/WO2015054175A1/en active Application Filing
- 2014-10-07 CR CR20160200A patent/CR20160200A/es unknown
- 2014-10-07 CN CN201480062094.3A patent/CN105722507A/zh active Pending
- 2014-10-07 AU AU2014332147A patent/AU2014332147A1/en not_active Abandoned
- 2014-10-07 EA EA201690753A patent/EA201690753A1/ru unknown
-
2016
- 2016-04-05 IL IL244923A patent/IL244923A0/en unknown
- 2016-04-08 PH PH12016500649A patent/PH12016500649A1/en unknown
- 2016-04-11 NI NI201600051A patent/NI201600051A/es unknown
- 2016-04-11 CL CL2016000838A patent/CL2016000838A1/es unknown
-
2018
- 2018-11-30 JP JP2018225287A patent/JP7403950B2/ja active Active
-
2019
- 2019-11-15 US US16/684,809 patent/US20200323849A1/en active Pending
-
2021
- 2021-02-12 JP JP2021020680A patent/JP2021073314A/ja active Pending
-
2023
- 2023-10-26 JP JP2023184173A patent/JP2024010118A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014332147A1 (en) | 2016-05-05 |
CN105722507A (zh) | 2016-06-29 |
JP2024010118A (ja) | 2024-01-23 |
PE20161342A1 (es) | 2016-12-31 |
IL244923A0 (en) | 2016-05-31 |
CA2926808A1 (en) | 2015-04-16 |
EP3054939A4 (en) | 2017-12-13 |
US20200323849A1 (en) | 2020-10-15 |
JP2021073314A (ja) | 2021-05-13 |
JP2019052171A (ja) | 2019-04-04 |
SG11201602791RA (en) | 2016-05-30 |
WO2015054175A1 (en) | 2015-04-16 |
EP3054939A1 (en) | 2016-08-17 |
EA201690753A1 (ru) | 2016-07-29 |
NI201600051A (es) | 2017-07-11 |
KR20160060143A (ko) | 2016-05-27 |
JP2016532667A (ja) | 2016-10-20 |
CL2016000838A1 (es) | 2016-11-25 |
US20150105358A1 (en) | 2015-04-16 |
PH12016500649A1 (en) | 2016-05-30 |
JP7403950B2 (ja) | 2023-12-25 |
MX2016004604A (es) | 2016-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
CR20140108A (es) | Compuesto de ciclopropanoamina | |
BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
AR099681A1 (es) | Composiciones de grapiprant y métodos para su utilización |